ReviewCardiovascular diabetology2015
Targeting metabolic disturbance in the diabetic heart.
Review in Cardiovascular diabetology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 62 citations in OpenAlex.
- Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Cardiovascular diabetology · 2017Trial
- Inferring multi-organ genetic connections using imaging and clinical data through Mendelian randomization.Nature biomedical engineering · 2026Article
- Article
- Stress hyperglycemia ratio and mortality in critically ill patients with heart failure: a retrospective cohort study from the MIMIC-IV database.BMC cardiovascular disorders · 2025Article
- Mechanistic exploration of hexokinase 2 and metabolism in diabetic cardiomyopathy.Molecular medicine reports · 2025Article
- Development of FGF21 Mutant with Potent Cardioprotective Effects in T2D Mice via FGFR1-AMPK-Mediated Inhibition of Oxidative Stress.International journal of molecular sciences · 2025Article
- Visit-to-visit glucose variability is associated with echocardiographic variables in people with type 2 diabetes: epidemiological and mendelian randomization approaches.Diabetology & metabolic syndrome · 2025Article
- Potential mechanisms of metabolic reprogramming induced by ischemia-reperfusion injury in diabetic myocardium.Journal of diabetes · 2024Article
- Diabetic Cardiomyopathy-From Basics through Diagnosis to Treatment.Biomedicines · 2024Review
- Fatty acid β-oxidation and mitochondrial fusion are involved in cardiac microvascular endothelial cell protection induced by glucagon receptor antagonism in diabetic mice.Journal of diabetes · 2023Article
- Network Pharmacology and Experimental Validation to Explore Mechanism of Tetrahydropalmatine on Acute Myocardial Ischemia.Chinese journal of integrative medicine · 2023Article
- "Medi-Mom": maternal mortality and extending postpartum Medicaid coverage.Pediatric research · 2023Article
- A new generation of sensors for non-invasive blood glucose monitoring.American journal of translational research · 2023Review
- The effect of nutraceuticals on multiple signaling pathways in cardiac fibrosis injury and repair.Heart failure reviews · 2022Review
- Diabetic cardiomyopathy: Clinical phenotype and practice.Frontiers in endocrinology · 2022Review
- Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.International journal of molecular sciences · 2021Review
- Article
- High prevalence of fragmented QRS on electrocardiography in Japanese patients with diabetes irrespective of metabolic syndrome.Journal of diabetes investigation · 2021Review
- The role of SIRT2 in vascular-related and heart-related diseases: A review.Journal of cellular and molecular medicine · 2021Review
- Expression profiling of circular RNAs and their potential role in early‑stage diabetic cardiomyopathy.Molecular medicine reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy is defined as ventricular dysfunction initiated by alterations in cardiac energy substrates in the absence of coronary artery disease and hypertension. In addition to the demonstrated burden of cardiovascular events associated with diabetes, diabetic cardiomyopathy partly explains why diabetic patients are subject to a greater risk of heart failure and a worse outcome after myocardial ischemia. The raising prevalence and accumulating costs of cardiovascular disease in diabetic patients underscore the deficiencies of tertiary prevention and call for a shift in medical treatment. It is becoming increasingly clearer that the effective prevention and treatment of diabetic cardiomyopathy require measures to regulate the metabolic derangement occurring in the heart rather than merely restoring suitable systemic parameters. Recent research has provided deeper insight into the metabolic etiology of diabetic cardiomyopathy and numerous heart-specific targets that may substitute or reinforce current strategies. From both experimental and translational perspectives, in this review we first discuss the progress made with conventional therapies, and then focus on the need for prospective metabolic targets that may avert myocardial vulnerability and functional decline in next-generation diabetic care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.